US Patent

US10925871 — Pharmaceutical compositions of sitagliptin

Formulation · Assigned to Cadila Healthcare Ltd · Expires 2035-02-25 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable oral pharmaceutical compositions of sitagliptin base and processes for their preparation.

USPTO Abstract

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US10925871
Jurisdiction
US
Classification
Formulation
Expires
2035-02-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Cadila Healthcare Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.